Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Sell
45
NSPR Quote, Financials, Valuation and Earnings
Last price:
$2.81
Seasonality move
:
-3.62%
Day range:
$2.81 - $2.93
52-week range:
$1.81 - $3.42
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
15.95x
P/B ratio:
1.80x
Volume:
14.9K
Avg. volume:
66.7K
1-year change:
33.02%
Market cap:
$74.6M
Revenue:
$6.2M
EPS (TTM):
-$0.72
Analysts' Opinion
-
Consensus RatingInspireMD has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, InspireMD has an estimated upside of 66.08% from its current price of $2.86.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $2.86.
Fair Value
-
According to the consensus of 0 analysts, InspireMD has 66.08% upside to fair value with a price target of -- per share.
NSPR vs. S&P 500
-
Over the past 5 trading days, InspireMD has underperformed the S&P 500 by -4.2% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
InspireMD does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
InspireMD has grown year-over-year revenues for 7 quarters straight. In the most recent quarter InspireMD reported revenues of $1.8M.
Earnings Growth
-
InspireMD has grown year-over-year earnings for 0 quarters straight. In the most recent quarter InspireMD reported earnings per share of -$0.16.
Enterprise value:
34.2M
EV / Invested capital:
0.83x
Price / LTM sales:
15.95x
EV / EBIT:
--
EV / Revenue:
5.01x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.66x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$1.5M
Return On Assets:
-57.43%
Net Income Margin (TTM):
-413.96%
Return On Equity:
-68.55%
Return On Invested Capital:
-68.55%
Operating Margin:
-467.51%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $5.5M | $5.5M | $6.8M | $1.6M | $1.8M | |
| Gross Profit | $1.2M | $1.5M | $1.5M | $438K | $414K | |
| Operating Income | -$17.7M | -$20.3M | -$29.9M | -$5.6M | -$8.5M | |
| EBITDA | -$17.5M | -$20M | -$29.7M | -$5.6M | -$8.4M | |
| Diluted EPS | -$2.27 | -$1.52 | -$0.72 | -$0.15 | -$0.16 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $13.3M | $40.1M | $24.7M | $46.7M | $46.4M | |
| Total Assets | $15.6M | $42.6M | $28.1M | $50M | $50.5M | |
| Current Liabilities | $2.6M | $3.7M | $4M | $4.7M | $7.3M | |
| Total Liabilities | $4.3M | $5.5M | $6.2M | $6.8M | $9.1M | |
| Total Equity | $11.3M | $37.1M | $21.9M | $43.3M | $41.4M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$15.2M | -$15.4M | -$19.3M | -$4M | -$5.7M | |
| Cash From Investing | $6.4M | -$12.2M | $4.4M | $6.4M | -$5.9M | |
| Cash From Financing | -$140K | $37.5M | $16.9M | -- | -$965K | |
| Free Cash Flow | -$15.7M | -$15.7M | -$20.6M | -$4.1M | -$6.1M | |
NSPR
Sector
Market Cap
$74.6M
$46.1M
Price % of 52-Week High
83.63%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
33.02%
-30.52%
Beta (5-Year)
0.985
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$2.93
200-day SMA
Buy
Level
$2.57
Bollinger Bands (100)
Buy
Level
2.53 - 2.93
Chaikin Money Flow
Buy
Level
65.3M
20-day SMA
Sell
Level
$2.99
Relative Strength Index (RSI14)
Sell
Level
48.63
ADX Line
Sell
Level
8.77
Williams %R
Buy
Level
-80.9524
50-day SMA
Buy
Level
$2.70
MACD (12, 26)
Buy
Level
0.06
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Neutral
Level
668.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.3597)
Sell
CA Score
(Annual)
Level (-1.7176)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (4.4712)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.
Stock Forecast FAQ
In the current month, NSPR has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NSPR average analyst price target in the past 3 months is --.
-
Where Will InspireMD Stock Be In 1 Year?
According to analysts, the consensus estimate is that InspireMD share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About InspireMD?
Analysts are divided on their view about InspireMD share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that InspireMD is a Sell and believe this share price will drop from its current level to --.
-
What Is InspireMD's Price Target?
The price target for InspireMD over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NSPR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for InspireMD is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of NSPR?
You can purchase shares of InspireMD via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase InspireMD shares.
-
What Is The InspireMD Share Price Today?
InspireMD was last trading at $2.81 per share. This represents the most recent stock quote for InspireMD. Yesterday, InspireMD closed at $2.86 per share.
-
How To Buy InspireMD Stock Online?
In order to purchase InspireMD stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
53
ARQQ alert for Dec 26
Arqit Quantum [ARQQ] is up 49.85% over the past day.
Buy
65
TSLL alert for Dec 26
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 3.73% over the past day.
Buy
75
SMLR alert for Dec 26
Semler Scientific [SMLR] is down 2.02% over the past day.
